Company profile for BioRay Pharmaceutical

BioRay Pharmaceutical

NEW Drugs in Dev: 12

ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

Contact Supplier

Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Contact Supplier

Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

Contact Supplier

LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Contact Supplier

pharmacompass-2-m-2026-03-23

Contact Supplier

VIRTUAL BOOTH
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

5 News #PharmaBuzz

media
5 News #PharmaBuzz

DEVELOPMENTS

19 Drugs in Development

19 Drugs in Development

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

BioRay is a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China, focusing on discovering, developing, manufacturing, and commercializing medicines for immune-mediated diseases and cancer. As a pioneer in China’s biopharmaceutical industry, BioRay started the R&D of biologics treatments in 2003 as a core business division of Hisun Pharmaceutical, a specialty comprehensive pharmaceu...

BioRay is a commercial-stage biopharmaceutical company with a full suite of end-to-end capabilities in China, focusing on discovering, developing, manufacturing, and commercializing medicines for immune-mediated diseases and cancer. As a pioneer in China’s biopharmaceutical industry, BioRay started the R&D of biologics treatments in 2003 as a core business division of Hisun Pharmaceutical, a specialty comprehensive pharmaceutical group founded in 1956. In 2019, PAG, a leading Asia-focused private equity firm, acquired the control of BioRay with an investment of RMB3.8B (USD$540M for 58% ownership).

IPhEB RussiaIPhEB Russia

Not Confirmed

Not Confirmed

07-09 April, 2026

St.Petersburg, Russia
Health 2.0 ConferenceHealth 2.0 Conference

Not Confirmed

Not Confirmed

07-09 April, 2026

Las Vegas, U.S.A
ICMD ChinaICMD China

Not Confirmed

Not Confirmed

09-12 April, 2026

Shanghai, China

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Country

China

Address

Address

Shugang road 1, Jiaojiang, Taizhou

Telephone

Telephone

Email

enquiries@pharmacompass.com

Client Website

Website

https://www.bioraypharm.com/index.php?m=list&a=index&classid=10

Linkedin

https://www.linkedin.com/company/bioraypharm/

youtube

YouTube

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

BioRay's BR111 ADC Gets NMPA Clinical Trial Approval

10 Feb 2025

// PR NEWSWIRE

BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812

07 Nov 2023

// PR NEWSWIRE

Trial Application (IND) for BioRay's BR105 Injection Receives U.S. FDA Approval

24 Oct 2023

// PR NEWSWIRE

Zuberitamab (Anruixi®) has been approved for marketing in China

13 Sep 2023

// PR NEWSWIRE

BioRay Filed IND for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1

24 May 2023

// PR NEWSWIRE

Drugs in Development

Full Screen View

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Privacy policy
Terms and conditions
Disclaimers
Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

Market Place

Home

Menu

Post Enquiry

Market Place

Search